Refine
Has Fulltext
- yes (270)
Year of publication
Document Type
- Journal article (160)
- Doctoral Thesis (96)
- Complete part of issue (10)
- Conference Proceeding (3)
- Preprint (1)
Language
- English (152)
- German (115)
- Multiple languages (3)
Keywords
- multiple sclerosis (11)
- Endothel (9)
- Multiple Sklerose (9)
- EAE (8)
- B cells (7)
- Habichtskraut (7)
- Geobotanik (6)
- MS (6)
- Pemphigus (6)
- Pflanzengeographie (6)
Institute
- Institut für Anatomie und Zellbiologie (270) (remove)
Sonstige beteiligte Institutionen
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Naturalis Biodiversity Centre (2)
- Johns Hopkins School of Medicine (1)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (1)
BACKGROUND:
Oct4 is a transcription factor that plays a major role for the preservation of the pluripotent state in embryonic stem cells as well as for efficient reprogramming of somatic cells to induced pluripotent stem cells (iPSC) or other progenitors. Protein-based reprogramming methods mainly rely on the addition of a fused cell penetrating peptide. This study describes that Oct4 inherently carries a protein transduction domain, which can translocate into human and mouse cells.
RESULTS:
A 16 amino acid peptide representing the third helix of the human Oct4 homeodomain, referred to as Oct4 protein transduction domain (Oct4-PTD), can internalize in mammalian cells upon conjugation to a fluorescence moiety thereby acting as a cell penetrating peptide (CPP). The cellular distribution of Oct4-PTD shows diffuse cytosolic and nuclear staining, whereas penetratin is strictly localized to a punctuate pattern in the cytoplasm. By using a Cre/loxP-based reporter system, we show that this peptide also drives translocation of a functionally active Oct4-PTD-Cre-fusion protein. We further provide evidence for translocation of full length Oct4 into human and mouse cell lines without the addition of any kind of cationic fusion tag. Finally, physico-chemical properties of the novel CPP are characterized, showing that in contrast to penetratin a helical structure of Oct4-PTD is only observed if the FITC label is present on the N-terminus of the peptide.
CONCLUSIONS:
Oct4 is a key transcription factor in stem cell research and cellular reprogramming. Since it has been shown that recombinant Oct4 fused to a cationic fusion tag can drive generation of iPSCs, our finding might contribute to further development of protein-based methods to generate iPSCs. Moreover, our data support the idea that transcription factors might be part of an alternative paracrine signalling pathway, where the proteins are transferred to neighbouring cells thereby actively changing the behaviour of the recipient cell.
Cell-permeant recombinant Nanog protein promotes pluripotency by inhibiting endodermal specification
(2014)
A comprehensive understanding of the functional network of transcription factors establishing and maintaining pluripotency is key for the development of biomedical applications of stem cells. Nanog plays an important role in early development and is essential to induce natural pluripotency in embryonic stem cells (ESCs). Inducible gain-of-function systems allowing a precise control over time and dosage of Nanog activity would be highly desirable to study its vital role in the establishment and maintenance of pluripotency at molecular level. Here we engineered a recombinant cell permeable version of Nanog by fusing it with the cell penetrating peptide TAT. Nanog-TAT can be readily expressed in and purified from E. coli and binds to a consensus Nanog DNA sequence. At cellular level it enhances proliferation and self-renewal of ESCs in the absence of leukemia inhibitory factor (LIF). Nanog-TAT together with LIF acts synergistically as judged by enhanced clonogenicity and activation of an Oct4-promoter-driven GFP reporter gene. Furthermore Nanog-TAT, in the absence of LIF, promotes pluripotency by inhibiting endodermal specification in a Stat3-independent manner. Our results demonstrate that Nanog protein transduction is an attractive tool allowing control over dose and time of addition to the cells for studying the molecular control of pluripotency without genetic manipulation.
B cell aggregates in the central nervous system (CNS) have been associated with rapid disease progression in patients with multiple sclerosis (MS). Here we demonstrate a key role of carcinoembryogenic antigen-related cell adhesion molecule1 (CEACAM1) in B cell aggregate formation in MS patients and a B cell-dependent mouse model of MS. CEACAM1 expression was increased on peripheral blood B cells and CEACAM1\(^+\) B cells were present in brain infiltrates of MS patients. Administration of the anti-CEACAM1 antibody T84.1 was efficient in blocking aggregation of B cells derived from MS patients. Along these lines, application of the monoclonal anti-CEACAM1 antibody mCC1 was able to inhibit CNS B cell aggregate formation and significantly attenuated established MS-like disease in mice in the absence of any adverse effects. CEACAM1 was co-expressed with the regulator molecule T cell immunoglobulin and mucin domain −3 (TIM-3) on B cells, a novel molecule that has recently been described to induce anergy in T cells. Interestingly, elevated coexpression on B cells coincided with an autoreactive T helper cell phenotype in MS patients. Overall, these data identify CEACAM1 as a clinically highly interesting target in MS pathogenesis and open new therapeutic avenues for the treatment of the disease.
Introduction
B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients. Here, patients with either relapsing-remitting (n = 24) or secondary progressive (n = 6) MS presenting with an acute clinical relapse were screened for their B cell reactivity to brain antigens and were re-tested three to nine months later. Enzyme-linked immunospot technique (ELISPOT) was used to identify brain-reactive B cells in peripheral blood mononuclear cells (PBMC) directly ex vivo and after 96 h of polyclonal stimulation. Clinical severity of symptoms was determined using the Expanded Disability Status Scale (EDSS).
Results
Nine patients displayed B cells in the blood producing brain-specific antibodies directly ex vivo. Six patients were classified as B cell positive donors only after polyclonal B cell stimulation. In 15 patients a B cell response to brain antigens was absent. Based on the autoreactive B cell response we categorized MS relapses into three different patterns. Patients who displayed brain-reactive B cell responses both directly ex vivo and after polyclonal stimulation (pattern I) were significantly younger than patients in whom only memory B cell responses were detectable or entirely absent (patterns II and III; p = 0.003). In one patient a conversion to a positive B cell response as measured directly ex vivo and subsequently also after polyclonal stimulation was associated with the development of a clinical relapse. The evaluation of the predictive value of a brain antigen-specific B cell response showed that seven of eight patients (87.5%) with a pattern I response encountered a clinical relapse during the observation period of 10 months, compared to two of five patients (40%) with a pattern II and three of 14 patients (21.4%) with a pattern III response (p = 0.0005; hazard ratio 6.08 (95% confidence interval 1.87-19.77).
Conclusions
Our data indicate actively ongoing B cell-mediated immunity against brain antigens in a subset of MS patients that may be causative of clinical relapses and provide new diagnostic and therapeutic options for a subset of patients.
INTRODUCTION:
B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients. Here, patients with either relapsing-remitting (n = 24) or secondary progressive (n = 6) MS presenting with an acute clinical relapse were screened for their B cell reactivity to brain antigens and were re-tested three to nine months later. Enzyme-linked immunospot technique (ELISPOT) was used to identify brain-reactive B cells in peripheral blood mononuclear cells (PBMC) directly ex vivo and after 96 h of polyclonal stimulation. Clinical severity of symptoms was determined using the Expanded Disability Status Scale (EDSS).
RESULTS:
Nine patients displayed B cells in the blood producing brain-specific antibodies directly ex vivo. Six patients were classified as B cell positive donors only after polyclonal B cell stimulation. In 15 patients a B cell response to brain antigens was absent. Based on the autoreactive B cell response we categorized MS relapses into three different patterns. Patients who displayed brain-reactive B cell responses both directly ex vivo and after polyclonal stimulation (pattern I) were significantly younger than patients in whom only memory B cell responses were detectable or entirely absent (patterns II and III; p = 0.003). In one patient a conversion to a positive B cell response as measured directly ex vivo and subsequently also after polyclonal stimulation was associated with the development of a clinical relapse. The evaluation of the predictive value of a brain antigen-specific B cell response showed that seven of eight patients (87.5%) with a pattern I response encountered a clinical relapse during the observation period of 10 months, compared to two of five patients (40%) with a pattern II and three of 14 patients (21.4%) with a pattern III response (p = 0.0005; hazard ratio 6.08 (95% confidence interval 1.87-19.77).
CONCLUSIONS:
Our data indicate actively ongoing B cell-mediated immunity against brain antigens in a subset of MS patients that may be causative of clinical relapses and provide new diagnostic and therapeutic options for a subset of patients.
Background: During early prenatal stages of brain development, serotonin (5-HT)-specific neurons migrate through somal translocation to form the raphe nuclei and subsequently begin to project to their target regions. The rostral cluster of cells, comprising the median and dorsal raphe (DR), innervates anterior regions of the brain, including the prefrontal cortex. Differential analysis of the mouse 5-HT system transcriptome identified enrichment of cell adhesion molecules in 5-HT neurons of the DR. One of these molecules, cadherin-13 (Cdh13) has been shown to play a role in cell migration, axon pathfinding, and synaptogenesis. This study aimed to investigate the contribution of Cdh13 to the development of the murine brain 5-HT system.
Methods: For detection of Cdh13 and components of the 5-HT system at different embryonic developmental stages of the mouse brain, we employed immunofluorescence protocols and imaging techniques, including epifluorescence, confocal and structured illumination microscopy. The consequence of CDH13 loss-of-function mutations on brain 5-HT system development was explored in a mouse model of Cdh13 deficiency.
Results: Our data show that in murine embryonic brain Cdh13 is strongly expressed on 5-HT specific neurons of the DR and in radial glial cells (RGCs), which are critically involved in regulation of neuronal migration. We observed that 5-HT neurons are intertwined with these RGCs, suggesting that these neurons undergo RGC-guided migration. Cdh13 is present at points of intersection between these two cell types. Compared to wildtype controls, Cdh13-deficient mice display increased cell densities in the DR at embryonic stages E13.5, E17.5, and adulthood, and higher serotonergic innervation of the prefrontal cortex at E17.5.
Conclusion: Our findings provide evidence for a role of CDH13 in the development of the serotonergic system in early embryonic stages. Specifically, we indicate that Cdh13 deficiency affects the cell density of the developing DR and the posterior innervation of the prefrontal cortex (PFC), and therefore might be involved in the migration, axonal outgrowth and terminal target finding of DR 5-HT neurons. Dysregulation of CDH13 expression may thus contribute to alterations in this system of neurotransmission, impacting cognitive function, which is frequently impaired in neurodevelopmental disorders including attention-deficit/hyperactivity and autism spectrum disorders.
The pathophysiology of tremor in Parkinson’s disease (PD) is evolving towards a complex alteration to monoaminergic innervation, and increasing evidence suggests a key role of the locus coeruleus noradrenergic system (LC-NA). However, the difficulties in imaging LC-NA in patients challenge its direct investigation. To this end, we studied the development of tremor in a reserpinized rat model of PD, with or without a selective lesioning of LC-NA innervation with the neurotoxin DSP-4. Eight male rats (Sprague Dawley) received DSP-4 (50 mg/kg) two weeks prior to reserpine injection (10 mg/kg) (DR-group), while seven male animals received only reserpine treatment (R-group). Tremor, rigidity, hypokinesia, postural flexion and postural immobility were scored before and after 20, 40, 60, 80, 120 and 180 min of reserpine injection. Tremor was assessed visually and with accelerometers. The injection of DSP-4 induced a severe reduction in LC-NA terminal axons (DR-group: 0.024 ± 0.01 vs. R-group: 0.27 ± 0.04 axons/um\(^2\), p < 0.001) and was associated with significantly less tremor, as compared to the R-group (peak tremor score, DR-group: 0.5 ± 0.8 vs. R-group: 1.6 ± 0.5; p < 0.01). Kinematic measurement confirmed the clinical data (tremor consistency (% of tremor during 180 s recording), DR-group: 37.9 ± 35.8 vs. R-group: 69.3 ± 29.6; p < 0.05). Akinetic–rigid symptoms did not differ between the DR- and R-groups. Our results provide preliminary causal evidence for a critical role of LC-NA innervation in the development of PD tremor and foster the development of targeted therapies for PD patients.
Although the bone marrow contains most hematopoietic activity during adulthood, hematopoietic stem and progenitor cells can be recovered from various extramedullary sites. Cells with hematopoietic progenitor properties have even been reported in the adult brain under steady‐state conditions, but their nature and localization remain insufficiently defined. Here, we describe a heterogeneous population of myeloid progenitors in the leptomeninges of adult C57BL/6 mice. This cell pool included common myeloid, granulocyte/macrophage, and megakaryocyte/erythrocyte progenitors. Accordingly, it gave rise to all major myelo‐erythroid lineages in clonogenic culture assays. Brain‐associated progenitors persisted after tissue perfusion and were partially inaccessible to intravenous antibodies, suggesting their localization behind continuous blood vessel endothelium such as the blood‐arachnoid barrier. Flt3\(^{Cre}\) lineage tracing and bone marrow transplantation showed that the precursors were derived from adult hematopoietic stem cells and were most likely continuously replaced via cell trafficking. Importantly, their occurrence was tied to the immunologic state of the central nervous system (CNS) and was diminished in the context of neuroinflammation and ischemic stroke. Our findings confirm the presence of myeloid progenitors at the meningeal border of the brain and lay the foundation to unravel their possible functions in CNS surveillance and local immune cell production.
Pathological angiogenesis promotes tumor growth, metastasis, and atherosclerotic plaque rupture. Macrophages are key players in these processes. However, whether these macrophages differentiate from bone marrow-derived monocytes or from local vascular wall-resident stem and progenitor cells (VW-SCs) is an unresolved issue of angiogenesis. To answer this question, we analyzed vascular sprouting and alterations in aortic cell populations in mouse aortic ring assays (ARA). ARA culture leads to the generation of large numbers of macrophages, especially within the aortic adventitia. Using immunohistochemical fate-mapping and genetic in vivo-labeling approaches we show that 60% of these macrophages differentiate from bone marrow-independent Ly6c\(^{+}\)/Sca-1\(^{+}\) adventitial progenitor cells. Analysis of the NCX\(^{−/-}\) mouse model that genetically lacks embryonic circulation and yolk sac perfusion indicates that at least some of those progenitor cells arise yolk sac-independent. Macrophages represent the main source of VEGF in ARA that vice versa promotes the generation of additional macrophages thereby creating a pro-angiogenetic feedforward loop. Additionally, macrophage-derived VEGF activates CD34\(^{+}\) progenitor cells within the adventitial vasculogenic zone to differentiate into CD31\(^{+}\) endothelial cells. Consequently, depletion of macrophages and VEGFR2 antagonism drastically reduce vascular sprouting activity in ARA. In summary, we show that angiogenic activation induces differentiation of macrophages from bone marrow-derived as well as from bone marrow-independent VW-SCs. The latter ones are at least partially yolk sac-independent, too. Those VW-SC-derived macrophages critically contribute to angiogenesis, making them an attractive target to interfere with pathological angiogenesis in cancer and atherosclerosis as well as with regenerative angiogenesis in ischemic cardiovascular disorders.
Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein–kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells. Immune activation by FXII is mediated by dendritic cells in a CD87-dependent manner and involves alterations in intracellular cyclic AMP formation. Our study demonstrates that a member of the plasmatic coagulation cascade is a key mediator of autoimmunity. FXII inhibition may provide a strategy to combat MS and other immune-related disorders.
A recombinant plasmid was constructed containing the gene for bovine growth hormone joinea with the regulatory region and the region coding the signal sequence of the Escherichia coli alkaline phosphatase gene. In conditions of phosphorus starvation, which c~s derepression of alkaline phosphatase, expression was shown of the gene for bovine growth hormone, in addition to partial processing and secretion of protein into periplasm.
Biofabrication, including printing technologies, has emerged as a powerful approach to the design of disease models, such as in cancer research. In breast cancer, adipose tissue has been acknowledged as an important part of the tumor microenvironment favoring tumor progression. Therefore, in this study, a 3D-printed breast cancer model for facilitating investigations into cancer cell-adipocyte interaction was developed. First, we focused on the printability of human adipose-derived stromal cell (ASC) spheroids in an extrusion-based bioprinting setup and the adipogenic differentiation within printed spheroids into adipose microtissues. The printing process was optimized in terms of spheroid viability and homogeneous spheroid distribution in a hyaluronic acid-based bioink. Adipogenic differentiation after printing was demonstrated by lipid accumulation, expression of adipogenic marker genes, and an adipogenic ECM profile. Subsequently, a breast cancer cell (MDA-MB-231) compartment was printed onto the adipose tissue constructs. After nine days of co-culture, we observed a cancer cell-induced reduction of the lipid content and a remodeling of the ECM within the adipose tissues, with increased fibronectin, collagen I and collagen VI expression. Together, our data demonstrate that 3D-printed breast cancer-adipose tissue models can recapitulate important aspects of the complex cell–cell and cell–matrix interplay within the tumor-stroma microenvironment
Bindung der extrazellulären Domäne von N-Cadherin an den Fibroblastenwachstumsfaktor-Rezeptor FGFR-1
(2008)
N-Cadherin, ein Mitglied der klassischen Cadherin Familie vermittelt durch homophile Bindungen der extrazellulären Domänen (EZD) zwischen benachbarten Zellen Zell-Zell-Kontakte. Im Nervensystem kontrolliert es zahlreiche Aufgaben wie beispielsweise die Ausbildung von Synapsen, die synaptische Plastizität, das Auswachsen von Axonen und deren richtungsgezielte Orientierung. In Untersuchungen zum Axonwachstum von cerebellären Körnerzellen konnte von Doherty et al. (1995, 1996) gezeigt werden, dass die isolierte EZDI-V von N-Cadherin über den FGFR-1 (Fibroblastenwachstumsfaktor-Rezeptor-1) ein richtungsvermitteltes Auswachsen von Axonen verursacht. Basierend auf diesen Beobachtungen wurde ein Bindungsmodell erstellt (Doherty et al., 1996). Dieses geht davon aus, dass zwischen transdimeren N-Cadherin-Molekülen, über die Aminosäuren IDPVNGQ der EZD Wechselwirkungen mit den Aminosäuren HAV der EZD von FGFR-1 auftreten (siehe hierzu Abb. 17). Der dadurch dimerisierte FGFR-1 bewirkt innerhalb der Nervenzelle eine intrazelluläre Signaltransduktion, die in einem zielgerichteten Axonwachstum resultiert. Das Ziel der vorliegenden Arbeit war, dieses Bindungsmodell näher zu untersuchen. Ausgehend von den für N-Cadherin und FGFR-1 kodierenden cDNAs und entsprechenden Vektorsystemen wurden in CHO-Zellen stabile Zelllinien erstellt. Das zugrundeliegende Expressionssystem führte zu einem Ausschleusen der für die Experimente notwendigen Fc-Fusionsproteine in den Kulturüberstand. Eine daran anschließende auf Protein A basierende Affinitätschromatographie des Kulturüberstandes ermöglichte die Isolierung und Anreicherung der Fc-Fusionsproteine. Desweiteren wurden Expressionsvektoren verwendet, die für subzelluläre Lokalisationsuntersuchungen verwendet wurden. Zu Beginn der Bindungsstudien wurde Untersuchungen zum Axonwachstum cerebellärer Körnerzellen durchgeführt. Diese dienten zum einen der Überprüfung der von Doherty und Walsh (1996) durchgeführten Experimente zum Längenwachstum cerebellärer Körnerzellen in Gegenwart ausgewählter Zelladhäsionsmoleküle (NCAM, L1 und N-Cadherin), zum anderen dienten sie der Überprüfung der Funktionalität der FGFR-1-und N-Cadherin-spezifischen Peptide (HAV und IDPVNGQ). Wie zu erwarten wurde durch Zugabe von N-Cadherin EZDI-V ein Axonlängenwachstum festgestellt, dass durch Zugabe der HAV- und IDPVNGQ-Peptide inhibiert wurde. Für den Auschluß der Wirkung von Fremdproteinen wurden in der vorliegenden Arbeit direkte Bindungsstudien durchgeführt. Hierzu wurden sowohl ELISA- als auch in Dot-Blot-Experimente durchgeführt. Diese ergaben eine Wechselwirkung der EZD von FGFR-1 und N-Cadherin. Eine von DsRed-FGFR-1 abhängige Lokalisation von GFP-N-Cadherin in CHO-Zellen deutete ebenfalls auf eine Interaktion hin. Nähere Bindungsstudien zeigten, dass die Bindungsmotive IDPVNGQ und HAV für eine Wechselwirkung der FGFR-1- und N-Cadherin-spezifischen EZDs bedeutungslos sind. Auch an der Laserpinzette durchgeführte Untersuchungen ergaben, das Wechselwirkungen zwischen N-Cadherin (auf Mikroperlen immobilisiert) und PC12-Zellen in Gegenwart der inhibierenden IDPVNGQ- und HAV-Peptide nicht verhindert werden konnten. Zusammenfasssend ist es gelungen zum ersten Mal eine direkte Wechselwirkung zwischen N-Cadherin und FGFR-1 nachzuweisen. Allerdings konnte in Kompetitionsexperimenten eine Bedeutung der postulierten Bindungsmotive nicht bestätigt werden.
Multiple sclerosis (MS) is the most prevalent neurological disease of the central nervous system (CNS) in young adults and is characterized by inflammation, demyelination and axonal pathology that result in multiple neurological and cognitive deficits. The focus of MS research remains on modulating the immune response, but common therapeutic strategies are only effective in slowing down disease progression and attenuating the symptoms; they cannot cure the disease. Developing an option to prevent neurodegeneration early on would be a valuable addition to the current standard of care for MS. Based on our results we suggest that application of nimodipine could be an effective way to target both neuroinflammation and neurodegeneration. We performed detailed analyses of neurodegeneration in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, and in in vitro experiments regarding the effect of the clinically well-established L-type calcium channel antagonist nimodipine. Nimodipine treatment attenuated the course of EAE and spinal cord histopathology. Furthermore, it promoted remyelination. The latter could be due to the protective effect on oligodendrocytes and oligodendrocyte precursor cells (OPCs) we observed in response to nimodipine treatment. To our surprise, we detected calcium channel-independent effects on microglia, resulting in apoptosis. These effects were cell type-specific and independent of microglia polarization. Apoptosis was accompanied by decreased levels of nitric oxide (NO) and inducible NO synthase (iNOS) in cell culture as well as decreased iNOS expression and reactive oxygen species (ROS) activity in EAE. Overall, application of nimodipine seems to generate a favorable environment for regenerative processes and could therefore be a novel treatment option for MS, combining immunomodulatory effects while promoting neuroregeneration.
Eine Reihe mehrtägiger Suchexkur-sionen / Transekte in verschiedene Regionen Bayerns in den Jahren 2011 bis 2014 waren der Gattung Taraxacum gewidmet. Unter den gesammelten und beobachteten Arten ist Taraxacum broddesonii (sect. Ruderalia / Taraxacum) neu für Deutschland. Neu für Bayern sind Taraxacum fusciflorum, marklundii, spiculatum (sect. Hamata) und Taraxacum acroglossum, atroviride, clarum, floccosum, freticola, glossodon, hemicyclum, homoschistum, infuscatum, intumescens, lacinulatum, leucopodum, lundense, ottonis, pallidipes, praestabile, pseudoretroflexum, pulverulentum, saxonicum, sellandii, sundbergii, uncidentatum, uniforme, violaceinervosum (sect. Ruderalia / Taraxacum). Taraxacum lojoënse wird als ältester und korrekter Name für T. lippertianum und T. matricium und wahrscheinlich auch für T. ampelophytum und T. debrayi angesehen. Seltenere Arten sind abgebildet.
1994 wurde von Gründemann et al. der erste organische Kationentransporter, der rOCT1 beschrieben. Es wurden bereits einige Aminosäuren identifiziert, die bei der Bindung kationischer Substanzen beteiligt sind. Hierbei handelt es sich um Phenylalanin 160 der zweiten Transmembrandomäne, Tryptophan 218, Tyrosin 222 und Threonin 226 der vierten Transmembrandomäne, um Arginin 440, Leucin 447, Glutamin 448 der zehnten und um Aspartat 475 der elften Transmembrandomäne. Hintergrund der Versuche dieser Arbeit war das im Jahre 2005 von Sturm et al. identifizierte Cystein 451. Es liegt zwischen der zehnten und elften Transmembrandomäne. Cystein 451 ist wahrscheinlich auf Grund seiner Lage im Strukturmodell nicht direkt an der Bindung von Substraten beteiligt. Es wird vermutet, dass die Mutation des Cysteins 451 die Positionen von Aminosäuren in der Bindungsstelle verändert. Daher wurden die Mutante C451M, die Doppelmutanten L447F/C451M, L447Y/C451M und die Dreifachmutante Y222F/L447F/C451M mittels Tracer-Fluxexperimenten hinsichtlich der Hemmung der Tetraethylammonium-Aufnahme durch Kortikosteron und durch Tetrabutylammonium untersucht. Die Mutation C451M steigert verglichen mit dem rOCT1-Wildtyp die Affinität für Kortikosteron, jedoch sinkt bei dieser Mutante die TBuA-Affinität. Man nimmt nun aufgrund dieser Mutageneseversuche und den bereits zuvor generierten Modellen des rOCT1 an, dass aufgrund seiner Lage Cystein 451 nicht direkt an der Bindung von Substraten beteiligt ist, sondern einen indirekten Effekt auf die Substratbindungsregion des Transporters ausübt. Weiterhin wurde festgestellt, dass die Mutanten L447Y/C451M und L447F/C451M gegensätzliche Affinitäten für TBuA und Kotikosteron haben. Tauscht man das Leucin an Position 447 gegen ein Tyrosin aus, so wird der Transporter weniger affin für Kortikosteron, jedoch steigt die TBuA-Affinität. Tauscht man das Leucin gegen ein Phenylalanin aus, verhält es sich gegensätzlich. Die Position 222 scheint weder an der TBuA-Bindung, noch an der Bindung von Kortikosteron maßgeblich beteiligt zu sein.
Die vorliegende Arbeit hatte zum Ziel, neuroendokrine Zellen in den Atemwegen bei Mäusen zu untersuchen, welche Kontakt zu sensorischen Nervenfasern ausbilden. In vorangegangenen Versuchen konnte bereits die Menge des ausgeschütteten CGRPs nach Stimulation mit Bitterstoffen bestimmt werden. Die Methode zur Messung der Freisetzung von CGRP aus verschiedenen Organen wurde von Prof. Reeh und seiner Arbeitsgruppe etabliert. Ziel der vorliegenden Arbeit war es, zu untersuchen, woher das ausgeschüttete CGRP kommt und ob die Stimulation von Bürstenzellen mit Bitterstoffen zur Ausschüttung von CGRP aus den neuroendokrinen Zellen führt. Anhand der elektronenmikroskopischen Auswertung und der dreidimensionalen Rekonstruktion konnte gezeigt werden, dass es Kontakt zwischen den neuroendokrinen Zellen im Epithel der Trachea und sensorischen Nervenfasern gibt. Die immunhistochemischen Versuche zeigten, dass es nach Stimulation mit Denatonium höchstwahrscheinlich zur Ausschüttung von CGRP durch die intraepithelialen Fasern gekommen ist. Diese Annahme spiegelt sich in der veränderten Morphologie sowie der geringeren Quantität der intraepithelialen Fasern nach Stimulation mit Denatonium deutlich wider. Dass es weder bei der Anzahl der neuroendokrinen Zellen, noch bei der Erscheinung und Anzahl der extraepithelialen Fasern nach Denatoniumstimulation zu einer Veränderung gekommen ist, unterstützt diese Annahme ebenfalls. Im Hinblick auf die durchgeführten Versuche mit den TRPM5-gendefizienten Mäusen zeigte sich, dass die Stimulation mit Denatonium keine Auswirkungen auf die Anzahl der neuroendokrinen Zellen hatte. Dieses Ergebnis unterstützt die Erkenntnisse der vorangegangenen Untersuchungen, welche gezeigt haben, dass das CGRP nicht von den neuroendokrinen Zellen ausgeschüttet wurde. Des Weiteren lässt das Ergebnis darauf schließen, dass die Ausschüttung von CGRP nicht abhängig von der Anwesenheit von Bürstenzellen ist. Insgesamt zeigen die Untersuchungen, dass es nach Stimulation mit Bittersubstanzen zu einer CGRP-Ausschüttung durch die intraepithelialen Fasern gekommen ist. Interessant wäre es weiterhin zu klären, welche Effekte diese Ausschüttung bewirkt und welche Bedeutung der Freisetzung von Substanz P in diesem Zusammenhang zukommt.
Die Stabiltät und Integrität der Epidermis beruht zu einem großen Teil auf der intakten Funktion der Desmosomen. Diese fleckförmigen Zellkontakte vermitteln extrazellulär die Haftung zwischen den Keratinozyten durch Desmocadherine und sind intrazellulär über Adaptorproteine im Intermediärfilamentsystem des Zellskeletts verankert. Diese Funktion ist bei der Autoimmunerkrankung Pemphigus gestört, die zu intraepidermaler Blasenbildung durch Akantholyse der Keratinozyten führt. Pemphigus vulgaris (PV) und Pemphigus foliaceus (PF) stellen die beiden Hauptvarianten dar, wobei PV durch Autoantikörper gegen die Desmocadherine Desmoglein (Dsg) 3 und oftmals zusätzlich gegen Dsg 1, PF durch Autoantikörper nur gegen Dsg 1 gekennzeichnet ist. Rho-GTPasen sind zelluläre Regulatorproteine, die das Aktinzytoskelett und verschiedene Zellkontakte beeinflussen. Die vorliegende Arbeit beschäftigte sich mit dem Einfluss von Rho-GTPasen bei der Regulation von desmosomal vermittelter Adhäsion. In einem zweiten Teil wurde die Beteiligung von Rho-GTPasen bei den Pemphigusvarianten PV und PF näher charakterisiert. Für den ersten Abschnitt wurden bakterielle Toxine verwendet, die spezifisch Rho GTPasen aktivieren bzw. inhibieren, während für den zweiten Teil IgG-Fraktionen von PV- und PF-Patienten in Kombination mit aktivierenden Toxinen zur Anwendung kamen. Eine Inhibition der drei Hauptvertreter der Rho-GTPasen in kultivierten Keratinozyten und humaner Epidermis führte zu einer Rarefizierung des Aktinfilamentsystems, zu Verlust von membranständig lokalisiertem Dsg 1 und 3 und zu Zelldissoziation sowie zu verminderter Dsg 1 und 3-vermittelter Haftung von Mikroperlen auf der Oberfläche von Keratinozyten. Die Aktivierung der GTPasen resultierte in vermehrter linearisierter Darstellbarkeit von Aktin und Dsg 3 an den Zellgrenzen und einer verstärkten Dsg-vermittelten Haftung. Pemphigus-IgG führten ebenfalls zu Zelldissoziation und Verlust von Dsg-Immunreaktivität in Keratinozytenkulturen, zu Spaltbildung in humaner Epidermis und zum Verlust der durch Dsg 1 und Dsg 3 vermittelten Adhäsion. Dies ging einher mit einer vermehrten Menge an nicht am Zytoskelett verankerten Dsg 3 und wurde durch eine p38MAPK-abhängige Verminderung der Aktivität von Rho A moduliert. Die Aktivierung von Rho A verhinderte die Ausbildung der Pemphigus-induzierten Effekte nahezu vollständig. Zusammenfassend regulieren Rho-GTPasen die desmosomale Haftung in Keratinozyten. Die Daten zeigen weiterhin, dass Pemphigus-IgG durch eine Inhibition von Rho A diese Regulation beeinträchtigt, was zu Schwächung der Zytoskelettverankerung von Desmogleinen und zu Haftungsverlust und Spaltbildung führt. Somit ist Rho A ein wichtiger Faktor der Pemphigus-Pathogenese und stellt einen Erfolg versprechenden Ansatzpunkt zur Entwicklung neuer Therapieoptionen dar.
Background: Dendritic cells (DCs) rendered suppressive by treatment with mitomycin C and loaded with the autoantigen myelin basic protein demonstrated earlier their ability to prevent experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis (MS). This provides an approach for prophylactic vaccination against autoimmune diseases. For clinical application such DCs are difficult to generate and autoantigens hold the risk of exacerbating the disease.
Methods: We replaced DCs by peripheral mononuclear cells and myelin autoantigens by glatiramer acetate (Copaxone ®), a drug approved for the treatment of MS. Spleen cells were loaded with Copaxone®, incubated with mitomycin C (MICCop) and injected into mice after the first bout of relapsing-remitting EAE. Immunosuppression mediated by MICCop was investigated in vivo by daily assessment of clinical signs of paralysis and in in vitro restimulation assays of peripheral immune cells. Cytokine profiling was performed by enzyme-linked immunosorbent assay (ELISA). Migration of MICCop cells after injection was examined by biodistribution analysis of 111Indium-labelled MICCop. The number and inhibitory activity of CD4+CD25+FoxP3+ regulatory T cells were analysed by histology, flow cytometry and in vitro mixed lymphocyte cultures. In order to assess the specificity of MICCop-induced suppression, treated EAE mice were challenged with the control protein ovalbumin. Humoral and cellular immune responses were then determined by ELISA and in vitro antigen restimulation assay.
Results: MICCop cells were able to inhibit the harmful autoreactive T-cell response and prevented mice from further relapses without affecting general immune responses. Administered MICCop migrated to various organs leading to an increased infiltration of the spleen and the central nervous system with CD4+CD25+FoxP3+ cells displaying a suppressive cytokine profile and inhibiting T-cell responses.
Conclusion: We describe a clinically applicable cell therapeutic approach for controlling relapses in autoimmune encephalomyelitis by specifically silencing the deleterious autoimmune response.